astroesophageal reflux disease (GERD) is a frequently occurring condition with 7% to 10% of the population experiencing heartburn weekly. GERD has routinely been identified using biological markers such as erosions. However, erosions are often not present in patients with heartburn and up to 50% of patients have GERD without macroscopic oesophagitis. Documentation of oesophagitis, as a biological marker, is usually not available to the primarycare clinician, and recent guidelines for GERD management recommend an empirical approach with a therapeutic trial of antisecretory agents for patients with no alarm symptoms. Impairment of health-related quality of life (HRQoL) has been proposed as an important element of the definition of GERD. Therefore, tools to assess how symptoms of GERD relate to and impair patientsâ€™ HRQoL are important for a better understanding of diagnosis and treatment. Indeed, adequate control of symptoms of GERD has been defined as a sustained reduction of symptoms to a level that does not significantly impair HRQoL. Furthermore, the speed of the change in HRQoL during therapy may influence the choice of the treatment drug. In a prospective, randomised, double-blind comparative study, after seven days of treatment, HRQoL scores in all scales improved to a greater degree in pantoprazole-treated patients than in nizatidine-treated patients. In comparison to baseline, 2 SF-36 domains (bodily pain and vitality) and the GSRS reflux score showed a statistically significant difference between the two treatment groups. After 28 days of treatment, the changes in scores remained statistically significant in favour of pantoprazole. Results of this study confirm the value of pantoprazole as a possible diagnostic tool in the assessment of GERD since pantoprazole rapidly improves both symptoms and HRQoL of GERD patients with heartburn. The HRQoL results using pantoprazole showed complete relief of heartburn after 28 days produced in 63% of patients. This is consistent with the early development of pharmacological tolerance to H 2 -RAs and with the sustained and profound acid inhibition achieved by pantoprazole. On the first day of a 28-day period of therapy, pantoprazole is as potent as the maximal inhibitory efficacy of ranitidine on intragastric acidity.
Rapid improvememnt of symptoms and HRQol

Statistically significant benefits
In this study, HRQoL improved to a significantly greater extent in EE than in ENRD patients. While both drugs resulted in a comparable HRQoL improvement in ENRD patients, pantoprazole produced greater improvement in EE patients. Similar results were observed for symptom relief. Complete heartburn relief was seen in 70% of the pantoprazoletreated group and in 34% of the nizatidine group in EE patients. In another large comparative trial of GERD patients with grade 0 and mild EE, pantoprazole 20mg od achieved statistically significant therapeutic gain in complete relief of heartburn in comparison to ranitidine 150mg bid (88% versus 69%, p<0.001). In summary, for GERD patients treated on the basis of their heartburn without the use of endoscopy, HRQoL improves more rapidly and to a greater extent after treatment with pantoprazole 40mg od than after treatment with nizatidine 150mg bid. The superiority of pantoprazole was sustained during the first 28 days of therapy. It appears that during acute treatment of GERD, for patients who exhibit heartburn as their main symptom, without any alarm features, the degree of symptom control is strongly predictive of improvement in their HRQoL. Thus, at the primarycare level, these results favour the use of a PPI, such as pantoprazole, for the initial treatment of heartburn and reflux symptoms, rather than an H 2 -RA. 
